These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Chan RJ; Leedy MB; Munugalavadla V; Voorhorst CS; Li Y; Yu M; Kapur R Blood; 2005 May; 105(9):3737-42. PubMed ID: 15644411 [TBL] [Abstract][Full Text] [Related]
4. Genetic disruption of the scaffolding protein, Kinase Suppressor of Ras 1 (KSR1), differentially regulates GM-CSF-stimulated hyperproliferation in hematopoietic progenitors expressing activating PTPN11 mutants D61Y and E76K. Yang Z; Chen M; Sitarski SA; Saadatzadeh T; Yin F; Yu M; Yang FC; Chan RJ Leuk Res; 2011 Jul; 35(7):961-4. PubMed ID: 21555152 [TBL] [Abstract][Full Text] [Related]
5. Shp2 function in hematopoietic stem cell biology and leukemogenesis. Nabinger SC; Chan RJ Curr Opin Hematol; 2012 Jul; 19(4):273-9. PubMed ID: 22504523 [TBL] [Abstract][Full Text] [Related]
6. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Chan G; Kalaitzidis D; Usenko T; Kutok JL; Yang W; Mohi MG; Neel BG Blood; 2009 Apr; 113(18):4414-24. PubMed ID: 19179468 [TBL] [Abstract][Full Text] [Related]
7. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells. Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766 [TBL] [Abstract][Full Text] [Related]
8. Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Chen L; Chen W; Mysliwski M; Serio J; Ropa J; Abulwerdi FA; Chan RJ; Patel JP; Tallman MS; Paietta E; Melnick A; Levine RL; Abdel-Wahab O; Nikolovska-Coleska Z; Muntean AG Leukemia; 2015 Jun; 29(6):1290-300. PubMed ID: 25650089 [TBL] [Abstract][Full Text] [Related]
9. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects. Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J Elife; 2022 May; 11():. PubMed ID: 35535491 [TBL] [Abstract][Full Text] [Related]
10. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Chan G; Cheung LS; Yang W; Milyavsky M; Sanders AD; Gu S; Hong WX; Liu AX; Wang X; Barbara M; Sharma T; Gavin J; Kutok JL; Iscove NN; Shannon KM; Dick JE; Neel BG; Braun BS Blood; 2011 Apr; 117(16):4253-61. PubMed ID: 21398220 [TBL] [Abstract][Full Text] [Related]
11. Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia. Zhang W; Chan RJ; Chen H; Yang Z; He Y; Zhang X; Luo Y; Yin F; Moh A; Miller LC; Payne RM; Zhang ZY; Fu XY; Shou W J Biol Chem; 2009 Aug; 284(33):22353-22363. PubMed ID: 19509418 [TBL] [Abstract][Full Text] [Related]
12. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Mohi MG; Williams IR; Dearolf CR; Chan G; Kutok JL; Cohen S; Morgan K; Boulton C; Shigematsu H; Keilhack H; Akashi K; Gilliland DG; Neel BG Cancer Cell; 2005 Feb; 7(2):179-91. PubMed ID: 15710330 [TBL] [Abstract][Full Text] [Related]